Your browser doesn't support javascript.
COVID-19, adaptative immune response and metabolic-associated liver disease.
Miele, Luca; Napodano, Cecilia; Cesario, Alfredo; De Magistris, Antonio; Pocino, Krizia; Basile, Umberto; Rapaccini, Gian L; Gasbarrini, Antonio; Grieco, Antonio.
  • Miele L; Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
  • Napodano C; Dipartimento di Medicina e Chirurgia Traslazionale, Scuola di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Cesario A; Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
  • De Magistris A; Dipartimento di Medicina e Chirurgia Traslazionale, Scuola di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Pocino K; Open Innovation Manager, Scientific Directorate, Fondazione Policlinico Universitario A.Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Basile U; Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
  • Rapaccini GL; Dipartimento di Medicina e Chirurgia Traslazionale, Scuola di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Gasbarrini A; Dipartimento di Scienze di laboratorio e infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Grieco A; Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
Liver Int ; 41(11): 2560-2577, 2021 11.
Article in English | MEDLINE | ID: covidwho-1434779
ABSTRACT
Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID-19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low-grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non-alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID-19 can have a worse outcome of COVID-19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID-19 complexity and to improve knowledge on its pathophysiology.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Non-alcoholic Fatty Liver Disease / COVID-19 / Metabolic Diseases Type of study: Reviews / Risk factors Limits: Humans Language: English Journal: Liver Int Journal subject: Gastroenterology Year: 2021 Document Type: Article Affiliation country: Liv.15061

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Non-alcoholic Fatty Liver Disease / COVID-19 / Metabolic Diseases Type of study: Reviews / Risk factors Limits: Humans Language: English Journal: Liver Int Journal subject: Gastroenterology Year: 2021 Document Type: Article Affiliation country: Liv.15061